Janux Therapeutics, Inc. (JANX) Stock Price & Analysis

Janux Therapeutics, Inc. (JANX) closed at USD 18.05 on Wednesday, October 28, 2026, up 4.58% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 17.26; the Oct 28, 2026 session ranged USD 16.89–18.07 on volume of 984,103 shares. Market capitalization is $1.10B, with a 52-week range of USD 12.12–35.34 (NGM). Source: Nexqual, retrieved October 29, 2026 at 04:05 UTC.

Also available as compact Markdown for AI agents: nexqual.com/JANX.md

Key facts (JANX)

• Last four reported quarters (through Jun 30, 2026): revenue $24.0M, net income -$103M (-427.5% margin), free cash flow -$41.9M (SEC filings).
• Insider open-market sales, last ~7 months: 2 Form 4 filings, $86K; 2 not under a Rule 10b5-1 plan ($86K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 2.11 on a 1–5 scale) (18 analysts), mean target USD 33.81 (range 14–60).
• Total return with dividends: 1Y -35.1% vs S&P 500 +13.6%; 5Y -25.9% vs S&P 500 +79.8%.
• Next earnings: 2026-11-05, EPS estimate USD -0.49, revenue estimate $6.4M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (JANX)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (JANX)

P/S 46.0x · P/B 1.2x · FCF yield -3.80% · Earnings yield -9.30%

Insider sales (SEC Form 4, open-market, last ~7 months) (JANX)

0 of 2 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (JANX)

Consensus Buy (mean 2.11 on a 1–5 scale), 18 analysts; mean target USD 33.81 (low 14, high 60).

Rating changes, last 120 days:

Total return (dividends reinvested) (JANX)

JANX earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

JANX recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

JANX suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 26, 2026.

JANX company outlook (results filed Aug 6, 2026)

• “Upcoming Milestones • Initial clinical data from the Phase 1 healthy volunteer study of JANX011 expected to be announced in the second half of 2026. • Clinical initiation of JANX013, a PSMA-targeted CD28 costimulatory TRACIr, expected in the second half of 2026. • Additional clinical data for JANX007 expected to be announced at a future medical congress in the first half of 2027.”
• “Such forward-looking statements are current only as of the date they are made, and Janux assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.”

Quoted word-for-word from the SEC 8-K results press release.

JANX analyst estimates and revisions

JANX options: expected move

Options price a move of about ±18.9% (±$3.33) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±2.2% on average.

30-day implied volatility 81.4% vs 46.1% realized over the last 30 trading days. Put/call ratio (volume) 2.51. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 04:05 UTC)

Technical Analysis (JANX)

Nexqual's technical model rates JANX "BUY" based on 4 bullish and 1 bearish signals across 127 daily candles, as of October 29, 2026 at 04:05 UTC.

Analyst Ratings (JANX)

Wall Street analysts rate JANX "Buy" based on 18 analysts, with a mean price target of USD 33.81 (range USD 14–60), per Nexqual as of October 29, 2026 at 04:05 UTC.

Earnings (JANX)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 04:05 UTC.

Financials & Fundamentals (JANX)

Source: Nexqual, October 29, 2026 at 04:05 UTC.

Financial Health Score (JANX)

Nexqual rates Janux Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 04:05 UTC.

Ownership (JANX)

Source: Nexqual, October 29, 2026 at 04:05 UTC.

Leadership (JANX)

Janux Therapeutics, Inc. is led by David Alan Campbell, President, Co-Founder, CEO & Director, per Nexqual as of October 29, 2026 at 04:05 UTC.

Major Backers & Investors (JANX)

Notable institutional backers of Janux Therapeutics, Inc. include RA Capital Management, L.P., Prosight Management, Lp, FMR, LLC, according to Nexqual as of October 29, 2026 at 04:05 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 04:05 UTC.

From Janux Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• We are an innovative clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying our proprietary technologies to our Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms.
• For example, our proprietary technology allows the masking and tumor activation of different T cell therapy modalities, including costimulation via CD28 engagement and our TRACIr platform.
• We are also applying our proprietary technology to create molecules designed to attract, redirect, or mobilize different types of immune cells to tumor sites that exclude or lack resident immune cells.
• We developed our proprietary albumin-binding domain derived from a llama antibody optimized for its ability to bind to albumin from both humans and NHPs, the primary preclinical species in which we conduct our in vivo experiments due to the similarity in target sequences and immune function with humans.

Partnerships

• In December 2020, we entered into a research collaboration and exclusive license agreement with Merck to develop TRACTr product candidates distinct from those in our internally developed pipeline.
• In January 2026, we entered into an exclusive license and collaboration agreement with Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types.

Legal & Regulatory Risks (Item 1A, quoted)

• The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product for which we obtain marketing approval.
• We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad.
• We are also bound by contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful.
• The complexity of announced or future tariffs may also increase the risk that we or our customers or suppliers may be subject to civil or criminal enforcement actions in the United States or foreign jurisdictions related to compliance with trade regulations.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 04:05 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt